Overview
This trial will study the safety and efficacy of cultured allogeneic adult umbilical cord derived mesenchymal stem cells delivered intravenously for the treatment of Polycystic Ovary Syndrome.
Description
Stem cell treatment has shown efficacy for PCOS in both human and animal studies. We are also reporting completer resolution of polycystic ovary syndrome (PCOS) in a young woman after a single intravenous injection of umbilical cord derived mesenchymal stem cells (UCDSC). We hypothesized that intravenous infusion of UCDSC can reduce or eliminate PCOS. Patients will receive roughly 2 million umbilical cord derived mesenchymal stem cells per kg of body weight. Hormone levels and ultrasound will be checked 3,6 and 12 months after treatment.
Eligibility
Inclusion Criteria: Ultrasound documented poly cystic ovary syndrome
Exclusion Criteria: Active infection, Active cancer, Chronic multisystem organ failure,
Pregnancy, Clinically significant abnormalities on pre-treatment laboratory evaluation,
Medical condition that would (based on the opinion of the investigator) compromise
patient's safety, Continued drug abuse, Previous organ transplant, Hypersensitivity to
sulfur, Inability to supply proper informed consent